<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02494024</url>
  </required_header>
  <id_info>
    <org_study_id>C2N-8E12-WW-104</org_study_id>
    <nct_id>NCT02494024</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, and Pharmacokinetics of C2N-8E12 in Subjects With Progressive Supranuclear Palsy</brief_title>
  <official_title>A Double-Blind, Placebo Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of C2N-8E12 in Subjects With Progressive Supranuclear Palsy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>C2N Diagnostics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>C2N Diagnostics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety and tolerability (maximum tolerated dose (MTD) within the
      specified dosing range) of single intravenous (IV) infusion of C2N-8E12 in patients with
      progressive supranuclear palsy (PSP).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study evaluates the safety, tolerability, pharmacokinetics, and maximum tolerated dose
      (within dosing range) of intravenous (IV) infusion of C2N-8E12 in 32 patients with
      progressive supranuclear palsy (PSP). Four sequential cohorts will receive increasing single
      doses of either C2N-8E12 or placebo. Out of every 4 patients enrolled 3 patients will receive
      drug and 1 will receive placebo. Study participants will be followed for a minimum of 2
      months post-treatment to monitor for the safety, tolerability, pharmacokinetics, and
      immunogenicity of C2N-8E12.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">August 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability, as measured by number of participants experiencing adverse events (AEs), serious AEs, and abnormalities in clinical laboratory tests, vital signs, ECGs, MRI, and physical and neurological exams.</measure>
    <time_frame>up to 4 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity as measured by the number of participants developing anti drug antibodies.</measure>
    <time_frame>up to 4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration vs time curve (AUC) of C2N-8E12</measure>
    <time_frame>up to 4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elimination half-life of C2N-8E12</measure>
    <time_frame>up to 4 months</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Progressive Supranuclear Palsy</condition>
  <arm_group>
    <arm_group_label>Single dose C2N-8E12 level 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single IV infusion of C2N-8E12</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single dose C2N-8E12 level 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single IV infusion of C2N-8E12</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single dose C2N-8E12 level 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single IV infusion of C2N-8E12</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single dose C2N-8E12 level 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single IV infusion of C2N-8E12</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single dose placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single IV infusion of placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Single dose C2N-8E12</intervention_name>
    <description>C2N-8E12 is a humanized recombinant anti-human tau antibody.</description>
    <arm_group_label>Single dose C2N-8E12 level 1</arm_group_label>
    <arm_group_label>Single dose C2N-8E12 level 2</arm_group_label>
    <arm_group_label>Single dose C2N-8E12 level 3</arm_group_label>
    <arm_group_label>Single dose C2N-8E12 level 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Single dose placebo</intervention_name>
    <description>Subjects will be block randomized to receive a single dose of C2N-8E12 or placebo in two blocks of 4 subjects (3:1, C2N-8E12:placebo) per cohort.</description>
    <arm_group_label>Single dose placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Meets NINDS-SPSP possible or probable criteria as modified for NNIPPS and AL-108-231
             clinical trials

          -  Brain MRI at Screening is consistent with PSP;

          -  Stable medications for Parkinsonism for at least 2 months prior to Screening;

          -  Agree to use protocol specified methods of contraception.

        Key Exclusion Criteria:

          -  Signs of a progressive neurological disorder that better meets the criteria for types
             of neurological disorders other than PSP;

          -  Currently on any other biologic or immunomodulatory therapy;

          -  Subjects that reside at a skilled nursing or dementia care facility;

          -  Diagnosis of any other significant unrelated neurological or psychiatric disorders
             that could account for cognitive deficits;

          -  Untreated major depression at baseline evaluation, based on clinical judgment and
             results in geriatric depression scale;

          -  Unable to tolerate MRI scan at Screening or any other contraindication to MRI;

          -  Any contraindication to or unable to tolerate lumbar puncture at Screening, including
             use of anti-coagulant medications.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adam Boxer, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCSF Memory and Aging Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, Los Angeles (UCLA)</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSD Department of Neurosciences</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94158</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida College of Medicine</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University Medical Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032-3795</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232-2551</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Health Presbyterian Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Yanamandra K, Kfoury N, Jiang H, Mahan TE, Ma S, Maloney SE, Wozniak DF, Diamond MI, Holtzman DM. Anti-tau antibodies that block tau aggregate seeding in vitro markedly decrease pathology and improve cognition in vivo. Neuron. 2013 Oct 16;80(2):402-414. doi: 10.1016/j.neuron.2013.07.046. Epub 2013 Sep 26.</citation>
    <PMID>24075978</PMID>
  </reference>
  <reference>
    <citation>Boxer AL, Lang AE, Grossman M, Knopman DS, Miller BL, Schneider LS, Doody RS, Lees A, Golbe LI, Williams DR, Corvol JC, Ludolph A, Burn D, Lorenzl S, Litvan I, Roberson ED, HÃ¶glinger GU, Koestler M, Jack CR Jr, Van Deerlin V, Randolph C, Lobach IV, Heuer HW, Gozes I, Parker L, Whitaker S, Hirman J, Stewart AJ, Gold M, Morimoto BH; AL-108-231 Investigators. Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial. Lancet Neurol. 2014 Jul;13(7):676-85. doi: 10.1016/S1474-4422(14)70088-2. Epub 2014 May 27.</citation>
    <PMID>24873720</PMID>
  </reference>
  <reference>
    <citation>Litvan I, Agid Y, Calne D, Campbell G, Dubois B, Duvoisin RC, Goetz CG, Golbe LI, Grafman J, Growdon JH, Hallett M, Jankovic J, Quinn NP, Tolosa E, Zee DS. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology. 1996 Jul;47(1):1-9. Review.</citation>
    <PMID>8710059</PMID>
  </reference>
  <reference>
    <citation>Yanamandra K, Jiang H, Mahan TE, Maloney SE, Wozniak DF, Diamond MI, Holtzman DM. Anti-tau antibody reduces insoluble tau and decreases brain atrophy. Ann Clin Transl Neurol. 2015 Mar;2(3):278-88. doi: 10.1002/acn3.176. Epub 2015 Jan 23.</citation>
    <PMID>25815354</PMID>
  </reference>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 30, 2015</study_first_submitted>
  <study_first_submitted_qc>July 7, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 10, 2015</study_first_posted>
  <last_update_submitted>July 25, 2017</last_update_submitted>
  <last_update_submitted_qc>July 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PSP</keyword>
  <keyword>C2N-8E12</keyword>
  <keyword>tauopathy</keyword>
  <keyword>Progressive Supranuclear Palsy</keyword>
  <keyword>Steele Richardson Olszewski Syndrome</keyword>
  <keyword>Humanized anti-tau antibody</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paralysis</mesh_term>
    <mesh_term>Supranuclear Palsy, Progressive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

